Cargando…

Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study

BACKGROUND: Exposure to PM(2.5) will accelerate the progression of cardiovascular diseases. Air purifier can reduce the PM(2.5) exposure and theoretically alleviate the influence of PM(2.5) on patients with stable coronary artery disease (SCAD). However, few studies of the protective effect showed s...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhe, Wang, Qin, Li, Na, Xu, Chunyu, Li, Yunpu, Zhou, Jun, Liu, Liu, Zhang, Haijing, Mo, Yang, Han, Feng, Xu, Dongqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868303/
https://www.ncbi.nlm.nih.gov/pubmed/36699920
http://dx.doi.org/10.3389/fpubh.2022.1082327
_version_ 1784876504246648832
author Liu, Zhe
Wang, Qin
Li, Na
Xu, Chunyu
Li, Yunpu
Zhou, Jun
Liu, Liu
Zhang, Haijing
Mo, Yang
Han, Feng
Xu, Dongqun
author_facet Liu, Zhe
Wang, Qin
Li, Na
Xu, Chunyu
Li, Yunpu
Zhou, Jun
Liu, Liu
Zhang, Haijing
Mo, Yang
Han, Feng
Xu, Dongqun
author_sort Liu, Zhe
collection PubMed
description BACKGROUND: Exposure to PM(2.5) will accelerate the progression of cardiovascular diseases. Air purifier can reduce the PM(2.5) exposure and theoretically alleviate the influence of PM(2.5) on patients with stable coronary artery disease (SCAD). However, few studies of the protective effect showed significant results because the interferent effects of routine medication had not been taken into account. In order to explore the actual effect on patients with SCAD, we conducted a randomized single-blind crossover air purifier intervention trial. METHOD: Levels of PM(2.5) exposure during intervention and cardiovascular indicators (inflammation, coagulation, plaque stability, and blood lipids) after intervention were detected, meanwhile the information of drug use was obtained by questionnaire. The kinds of drug used by more than 20% of the subjects were sorted out. And the influence of these drugs on cardiovascular indicators was summarized through literature review. Based on that, the drug use was included as a variable in linear mixed effects models that used to analyze the associations between PM(2.5) exposure reduction by air purifier and cardiovascular indicators. RESULTS: The result revealed that the interpretation contribution rate of drug use was more than that of PM(2.5) exposure. The level of C-reactive protein significantly decreased by 20.93% (95%CI: 6.56%, 33.10%), 23.44% (95%CI: 2.77%, 39.39%) and 24.11% (95%CI: 4.21%, 39.69%) on lag1, lag01 and lag02 respectively, while the level of high-density lipoprotein cholesterol significantly increased by 5.10% (95%CI: 0.69%, 9.05%), 3.71% (95%CI: 0.92%, 6.60%) and 6.48% (95%CI: 2.58%, 10.24%) respectively on lag0, lag1 and lag01 associated with an interquartile range decrease of 22.51 μg/m(3) in PM(2.5) exposure. CONCLUSION: The study shows positive effects of air purifier on SCAD, and also provides methodological reference for future related research.
format Online
Article
Text
id pubmed-9868303
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98683032023-01-24 Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study Liu, Zhe Wang, Qin Li, Na Xu, Chunyu Li, Yunpu Zhou, Jun Liu, Liu Zhang, Haijing Mo, Yang Han, Feng Xu, Dongqun Front Public Health Public Health BACKGROUND: Exposure to PM(2.5) will accelerate the progression of cardiovascular diseases. Air purifier can reduce the PM(2.5) exposure and theoretically alleviate the influence of PM(2.5) on patients with stable coronary artery disease (SCAD). However, few studies of the protective effect showed significant results because the interferent effects of routine medication had not been taken into account. In order to explore the actual effect on patients with SCAD, we conducted a randomized single-blind crossover air purifier intervention trial. METHOD: Levels of PM(2.5) exposure during intervention and cardiovascular indicators (inflammation, coagulation, plaque stability, and blood lipids) after intervention were detected, meanwhile the information of drug use was obtained by questionnaire. The kinds of drug used by more than 20% of the subjects were sorted out. And the influence of these drugs on cardiovascular indicators was summarized through literature review. Based on that, the drug use was included as a variable in linear mixed effects models that used to analyze the associations between PM(2.5) exposure reduction by air purifier and cardiovascular indicators. RESULTS: The result revealed that the interpretation contribution rate of drug use was more than that of PM(2.5) exposure. The level of C-reactive protein significantly decreased by 20.93% (95%CI: 6.56%, 33.10%), 23.44% (95%CI: 2.77%, 39.39%) and 24.11% (95%CI: 4.21%, 39.69%) on lag1, lag01 and lag02 respectively, while the level of high-density lipoprotein cholesterol significantly increased by 5.10% (95%CI: 0.69%, 9.05%), 3.71% (95%CI: 0.92%, 6.60%) and 6.48% (95%CI: 2.58%, 10.24%) respectively on lag0, lag1 and lag01 associated with an interquartile range decrease of 22.51 μg/m(3) in PM(2.5) exposure. CONCLUSION: The study shows positive effects of air purifier on SCAD, and also provides methodological reference for future related research. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9868303/ /pubmed/36699920 http://dx.doi.org/10.3389/fpubh.2022.1082327 Text en Copyright © 2023 Liu, Wang, Li, Xu, Li, Zhou, Liu, Zhang, Mo, Han and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Liu, Zhe
Wang, Qin
Li, Na
Xu, Chunyu
Li, Yunpu
Zhou, Jun
Liu, Liu
Zhang, Haijing
Mo, Yang
Han, Feng
Xu, Dongqun
Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study
title Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study
title_full Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study
title_fullStr Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study
title_full_unstemmed Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study
title_short Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study
title_sort cardiovascular benefits of air purifier in patients with stable coronary artery disease: a randomized single-blind crossover study
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868303/
https://www.ncbi.nlm.nih.gov/pubmed/36699920
http://dx.doi.org/10.3389/fpubh.2022.1082327
work_keys_str_mv AT liuzhe cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT wangqin cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT lina cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT xuchunyu cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT liyunpu cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT zhoujun cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT liuliu cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT zhanghaijing cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT moyang cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT hanfeng cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy
AT xudongqun cardiovascularbenefitsofairpurifierinpatientswithstablecoronaryarterydiseasearandomizedsingleblindcrossoverstudy